Risk perception, knowledge about SARS-CoV-2, and perception towards preventive measures in Italy: a nationwide cross-sectional study

Introduction: After COVID-19 outbreak, governments adopted several containment measures. Risk perception and knowledge may play a crucial role since they can affect compliance with preventive measures. This study aimed to explore the extent and the associated factors of risk perception, knowledge regarding SARS-CoV2, and perception towards preventive measures among the Italian population. Methods: A nationwide cross-sectional study involving adults was conducted in April-May 2021: an online survey was distributed through social media. The outcomes were: Knowledge Score (KS) (0 to 100%: higher scores correspond to higher COVID-19-related knowledge); Risk Perception Score (RPS) (1 to 4: higher values indicate higher concern); Preventive measures Perception Score (PPS) (1 to 4: higher values indicate higher confidence). Multivariable regression models were performed. Results: A total of 1120 participants were included. Median KS was 79.5%  (IQR=72.7%-86.4%). Lower education and poor economic conditions were negatively associated with the KS.  Median RPS was 2.8 (IQR=2.4-3.2). Female gender, sharing house with a fragile person, suffering from a chronic disease, having a family member/close friend who contracted SARS-CoV-2 infection were positively associated with the RPS. Median PPS was 3.1 (IQR=2.8-3.4). Lower educational level was negatively associated with the PPS. Vaccine hesitancy was negatively associated with all three outcomes. The three scores were positively associated with each other. Conclusions: Fair levels of knowledge, risk perception and perception towards preventive measures were reported. Reciprocal relationships between the outcomes and a relevant relationship with vaccine hesitancy were highlighted. Further investigations should be focused on studying underlying determinants and consequences

Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection

Objectives. We investigated immune phenotypes of HIV+ patients who present late, considering late presenters (LPs, CD4+ < 350/μL and/or AIDS), advanced HIV disease (AHD, CD4+ < 200/μL and/or AIDS), and AIDS presenters (AIDS-defining condition at presentation, independently from CD4+). Methods. Patients newly diagnosed with HIV at our clinic between 2007–2011 were enrolled. Mann-Whitney/Chi-squared tests and logistic regression were used for statistics. Results. 275 patients were newly diagnosed with HIV between January/2007–March/2011. 130 (47%) were LPs, 79 (29%) showed AHD, and 49 (18%) were AIDS presenters. LP, AHD, and AIDS presenters were older and more frequently heterosexuals. Higher CD8+%, lower CD127+CD4+%, higher CD95+CD8+%, CD38+CD8+%, and CD45R0+CD38+CD8+% characterized LP/AHD/AIDS presentation. In multivariate analysis, older age, heterosexuality, higher CD8+%, and lower CD127+CD4+% were confirmed associated with LP/AHD. Lower CD4+ and higher CD38+CD8+% resulted independently associated with AIDS presentation. Conclusions. CD127 downregulation and immune activation characterize HIV+ patients presenting late and would be studied as additional markers of late presentation

Cellular fatty acid composition in film-forming strains of two physiological races of <i>Saccharomyces cerevisiae</i>

Eleven strains belonging to two physiological races of Saccharomyces cerevisiae endowed with different abilities of forming films at air-liquid interfaces were analysed in relation to cell fatty acid composition and cell hydrophobicity. Extensive individual differences in fatty acid profiles were observed both in the film and in the non-film phase. The ability of the cells to form a floating film seems to be an implicit strain character associated with an elevated unsaturation level and a mean chain length of fatty acid residues, as well as cellular hydrophobicities higher than those shown by non-film-forming strains belonging to the same species

iNKT cell phenotype and function in HIV-positive “Double Positive” (DP) and “Double Negative” (DN) patients.

<p>Gating strategy of flow cytometry analysis for staining of iNKT cell frequencies, phenotype and intracellular cytokine production in a representative HIV-positive individual (A); an example of staining for intracellular cytokines is also shown of a representative HIV-negative subject (B). PBMCs were gated on lymphocytes, and iNKT cells were visualized as CD3+, Vα24+ and CD1d-tetramer+. An example of CD161 surface staining is shown in the far right plot. iNKT frequency were comparable in DP and DN groups (C). iNKT cell phenotype was analyzed through the <i>ex vivo</i> expression of CD161 in DP (n = 10) and DN (n = 10) patients (D). DP subjects exhibited significantly higher levels of CD161 on iNKT cell surface compared to DN patients (p = .001). iNKT cell function was measured through the production of TNF and IFN-γ <i>ex vivo</i> (US) and following stimulation with PMA/ionomycin (n = 10 per group) (E, F) and α-GalCer (n = 5 per group) (G, H). Although DP and DN patients significantly increased TNF production upon PMA/ionomycin stimulation (p = .002 and p = .027 respectively), DP subjects showed higher TNF release both prior to (p = .049) and following PMA/ionomycin (E). Study groups exhibited similar frequencies of IFN-γ-producing iNKT cells both <i>ex vivo</i> and after stimulation with PMA/ionomycin (F). DP patients were characterized by significantly higher TNF release both prior to (p = .047) and following stimulation with α-GalCer (p = .021) (G). Similar results were obtained in terms of IFN-γ production, with a trend to higher cytokine production in DP subjects following iNKT-specific stimulation (p = .059) (H). FSC, Forward Scatter: SSC, Side Scatter. Each symbol represents an individual.</p

iNKT cell phenotype and function in HIV-positive “Bone Disease” (BD), “Cardiovascular Disease” (CD) and “Double Negative” (DN) patients.

<p>iNKT frequency was comparable among BD and DN groups (A). BD (n = 10) and DN (n = 10) showed similar CD161-expressing iNKT cell frequencies (B) and a significant increase in TNF production following PMA/ionomycin stimulation (p = .002 and p = .027 respectively). Despite a trend to higher spontaneous TNF release in BD patients (p = .075), comparable cytokine levels were recorded upon PMA/ionomycin (C). BD patients alone responded to PMA/ionomycin with significant IFN-γ production following stimulation (p = .0488) (D). Significantly higher TNF production was detected in BD subjects (p = .031) prior to α-GalCer stimulation. Upon α-GalCer stimulation, BD patients displayed a trend to significant increases in TNF release (p = .063), leading to higher cytokine levels in this population (p = .056) (E). No significant differences were noted in terms of IFN-γ production following α-GalCer, although BD patients tended to significant cytokine production (p = .063) (F). CD and DN showed comparable iNKT cell frequencies (G). CD (n = 10) and DN (n = 10) showed similar CD161-expressing iNKT cell frequencies (H). CD subjects showed higher TNF release both prior to (p = .005) and following stimulation with PMA/ionomycin (p = .029). Of note, DN patients alone responded to stimulation by significantly increasing TNF release from iNKT cells aspecific stimulation (p = .027) (I). In keeping with these results, the CD group displayed a trend to higher IFN-γ release after PMA/ionomycin stimulation (p = .052) (J). No statistical differences were noted between groups in terms of iNKT function following specific activation with α-GalCer (K, L). Horizontal lines indicate median values. Each symbol represents an individual.</p

Patient characteristics.

<p>DP: Double Positive; BD: Bone Disease; CD: Cardiovascular Disease; DN: Double Negative. MSM: Males Who Have Sex With Males. IVD: Intravenous Drug. HCV: Hepatitis C Virus. HAART: Highly Active Antiretroviral Therapy; PI: Protease Inhibitor; NNRTI: Non-Nucleoside Retroscriptase Inhibitor. DXA: Dual-energy X-ray absorptiometry. IMT: Intima Media Thickness. Data presented as: median (interquartile range, IQR) for continuous variables; absolute number (percentage) for categorical variables. p<0.05: ^aDP vs DN; ^bDP vs BD; ^cBD vs DN; ^dBD vs CD; ^eCD vs DN; ^fCD vs DP.</p><p>Patient characteristics.</p

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study

Introduction: We analyzed a cohort of patients with cancer and Sars-Cov-2 infec- tion from the Veneto Oncology Network registry across two pandemic time periods. Materials and methods: 761 patients with cancer and SARS-CoV-2 infection were included. Results: 198 patients were diagnosed during the first pandemic time period (TP1; February 2020 September 2020), 494 during TP2 before the vaccination campaign (TP2/pre-vaccination; September 2020-21 February 2021) and 69 in TP2/post-vaccination (22 February 2021-15 May 2021). TP2 vs TP1 patients were younger (p Z 0.004), showed more frequently a good perfor- mance status (p &lt; 0.001) and &lt;2 comorbidities (p Z 0.002), were more likely to be on active anticancer therapy (p Z 0.006). Significantly fewer patients in TP2 (3-4%) vs TP1 (22%) had an in-hospital potential source of infection (p &lt; 0.001). TP2 patients were more frequently asymptomatic (p Z 0.003). Significantly fewer patients from TP2 were hospitalized (p &lt; 0.001) or admitted to intensive care unit (p Z 0.006). All-cause mortality decreased from 30.3% in TP1, to 8.9% and 8.7% in the two TP2 periods (p &lt; 0.001), reflected by a significant reduction in Sars-Cov-2-related mortality (15.2%, 7.5% and 5.8% in the three consecutive time periods, p Z 0.004). Conclusions: Differences in clinical characteristics and features of Sars-Cov-2 infection be- tween TP1 and TP2 reflect the effects of protective measures and increased testing capacity. The lower mortality in TP2 is in line with a less frail population. However, the vast majority of death events in TP2 were related to COVID-19, reinforcing the priority to protect cancer patients